VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viatris Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.26−0.39 (-2.12%)
Close on Oct 19, 2026
- Market cap
- $21.24B
- P/E (TTM)
- –
- Dividend yield
- 2.63%
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
35.1%+3.3 pts over 5 years
Operating margin
-18.6%−16.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -3.0% | -4.2% | +3.7% | – | |
| Gross profit | -10.8% | -8.3% | +5.7% | – | |
| Free cash flow | -2.0% | -9.3% | +14.4% | – | |
| Dividend per share | 0.0% | 0.0% | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | 1.22 | 1.38 | |
| Net debt to EBITDA | – | 11.89× | 96.81× | |
| Interest coverage | – | -0.4× | -5.7× | |
| Inventory turnover | – | 2.0× | 2.4× | |
| Capex to revenue | – | 2.0% | 2.6% | |
| Diluted shares | – | 601M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Viatris generated $13.53B from operations and spent $2.95B on capital expenditure, dividends and share buybacks. 66% of that went back into the business.
Generated
$13.53B
Used
$2.95B
Capital expenditure$1.95B66%Dividends$00%Share buybacks$1.00B34%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero$2.32B
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income$2.32B vs –
- Less leverageLong-term debt to assets fell33.8% → 33.6%
- Better liquidityCurrent ratio rose1.65 → 1.38
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year38.15% → 35.06%
- More efficientAsset turnover rose0.31 → 0.34